sclc0617_S65.txt
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.580
- INTERFERON_GAMMA_RESPONSE+0.580
- INTERFERON_ALPHA_RESPONSE+0.550
- COAGULATION+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- TNFA_SIGNALING_VIA_NFKB+0.490
- COMPLEMENT+0.480
- ANGIOGENESIS+0.460
Top 10 suppressed
- MYC_TARGETS_V1-0.540
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V2-0.420
- MITOTIC_SPINDLE-0.410
- DNA_REPAIR-0.370
- OXIDATIVE_PHOSPHORYLATION-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.300
- MTORC1_SIGNALING-0.230
- PEROXISOME-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.952 |
| 2 | BS_3H71BH6Q | Ganglioglioma | — | 0.950 |
| 3 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.941 |
| 4 | BS_4EN8D8Y4 | low-grade glioma | — | 0.941 |
| 5 | BS_W97QQYKQ | Ganglioglioma | — | 0.940 |
| 6 | MDT-AP-2892 | Med | Medulloblastoma | 0.939 |
| 7 | ERR2598312 | fetal | fetal | 0.936 |
| 8 | SRR1382532 | GTEX | — | 0.935 |
| 9 | MDT-AP-2638 | Med | Medulloblastoma | 0.935 |
| 10 | sclcWD22563_S71.txt | — | cohortMD2 | 0.935 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| COAGULATION | 0.490 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.440 | Cobimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |